U.S. markets open in 4 hours 40 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
324.21-7.67 (-2.31%)
At close: 4:00PM EDT
321.00 -3.21 (-0.99%)
Pre-Market: 04:48AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close331.88
Bid322.20 x 1100
Ask322.30 x 800
Day's Range318.50 - 341.55
52 Week Range65.49 - 497.49
Avg. Volume19,468,982
Market Cap130.866B
Beta (5Y Monthly)1.49
PE Ratio (TTM)38.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-29% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MRNA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Moderna, Inc.
    Analyst Report: Moderna, Inc.Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Motley Fool

    2 Biotech Stocks Poised for Jaw-Dropping Growth

    Over the past 10 years, U.S. stocks have delivered outstanding returns for investors. The major stock indices such as the Dow Jones Industrial Average, the NASDAQ Composite, and the S&P 500 have all climbed by more than 200% during this boom period. For example, biotech innovators Axsome Therapeutics (NASDAQ: AXSM) and Moderna (NASDAQ: MRNA), along with electric-car giant Tesla (NASDAQ: TSLA), have all generated well over 1,000% returns on capital for investors in just the past three years.


    A Big Fund Slashed Its Stake in GameStop Stock. It Bought Moderna and Palantir.

    The Alaska Department of Revenue sold most of its GameStop stock in the third quarter. It initiated positions in Moderna and Palantir stock, and bulked up its holdings in Analog Devices stock.

  • Motley Fool

    Could Moderna Justify Its $129 Billion Valuation?

    The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?